The Value of Multimodal MR Imaging in Cognitive Assessment of Patients With Moderate Traumatic Brain Injury

Sponsor
First Affiliated Hospital Xi'an Jiaotong University (Other)
Overall Status
Recruiting
CT.gov ID
NCT06099210
Collaborator
Ankang Central Hospital (Other)
100
1
18
5.6

Study Details

Study Description

Brief Summary

The goal of this observational study is to learn about in The value of multimodal MR Imaging in cognitive assessment of patients with moderate traumatic brain injury. The main question it aims to answer is:

• The construction of the core injury model of cognitive impairment caused by moderate brain trauma takes multi-parameter MR scanning as the main line of research, centering on the analysis of cognitive impairment of white matter structure damage and brain function involved in the research institute, and conducts research on key scientific issues such as the validity verification of cognitive prognosis after moderate brain trauma.

Participants will be collected for MR, hematology and stool and neuropsychological Scale indicators in the study.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Glasgow coma scale

Detailed Description

According to the World Health Organization's (WHO) public health statistics on neurological diseases, it is expected that by 2030, neurological injuries caused by brain trauma will become the leading cause of disability of neurological diseases, and Alzheimer's disease and cerebrovascular disease combined two to three times. More than 50 million people worldwide suffer from TBI each year, and about half of the world's population may experience one or more TBI in their lifetime. As a potential risk factor, TBI will increase the risk of neurodegenerative diseases by 1.5 times, and up to 30%-70% of TBI patients will develop neurological symptoms. Brain injury is an important global medical, public health and social problem. Early diagnosis and effective treatment can effectively reduce the disability rate of patients and the incidence of neurological sequelae, which has become a hot topic in the international scientific research community. This study focuses on the construction of the core injury model of cognitive impairment caused by moderate traumatic brain injury, takes multi-parameter MR Scanning as the main line of research, and focuses on the analysis of cognitive impairment caused by white matter structure injury and brain function covariation involved in this study as the breakthrough point, and carries out research on key scientific issues such as the validity verification of cognitive prognosis after moderate traumatic brain injury.

This study was conducted mainly on moderate brain trauma, combined with related departments of neurosurgery, imaging, laboratory, rehabilitation and pain. The research objective is to collect 50 patients with brain trauma and 50 healthy control group from the First Affiliated Hospital of Xi'an Jiaotong University and Ankang Central Hospital. The magnetic resonance, hematology, stool and neuropsychology scale 3 indicators. Magnetic resonance examination: For patients with moderate craniocerebral trauma who meet the inclusion criteria, head MRI scans were performed in the subacute period after injury (within 10 to 21 days) and 3-6 months (chronic phase); for the control group with age, gender, education, skill and disease group and with no psychiatric or neurological diseases. The scanning sequence includes: (1) 3-pl (the positioning image requires the preservation of the whole brain, Including the overhead scalp to all the cerebellum) (check the parameters before scanning); (2) T2-FLAIR (brain condition prediction, If any abnormal lesion, The scan should be stopped immediately) (3) T1-weighted 3D-MPRAGE (4) DTI (5) Resting State (BOLD) (positioning line parallel to AC-PC line) (6) MAGiC (7) ASL 5. Neuropsychological evaluation: patients with moderate brain trauma before or within 48 hours after each scan; For healthy controls matched for sex, age, education, and literacy, Neuropsychological scale assessments were performed at 48 hours after completing the MRI examination. The scale includes pain after TBI, memory, executive function, information processing, TBI recovery, anxiety, and depression.6. Hematology and stool data collection: collect data of hematological markers (whole blood samples to our hospital (0 days), the first MR scan (10~21 days) and 24 hours before (3-6 months after injury) (3 mL * 2, serum samples 3 mL * 1 / time), collect stool samples (about 1mg) before the first MR scan and 24 hours before the second MR scan.

Study Design

Study Type:
Observational
Anticipated Enrollment :
100 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
The Value of Multimodal MR Imaging in Cognitive Assessment of Patients With Moderate Traumatic Brain Injury
Actual Study Start Date :
Jul 3, 2023
Anticipated Primary Completion Date :
Dec 31, 2024
Anticipated Study Completion Date :
Dec 31, 2024

Arms and Interventions

Arm Intervention/Treatment
Moderate traumatic brain injury

Intervention: Glasgow coma scale

Diagnostic Test: Glasgow coma scale
Closed tach brain injury due to external force was included according to the GCS score

Healthy control group

Outcome Measures

Primary Outcome Measures

  1. head MRI scans [in the subacute period after injury (within 10 to 21 days) and 3-6 months (chronic phase)]

    The scanning sequence includes: (1) 3-pl (the positioning image requires the preservation of the whole brain, Including the overhead scalp to all the cerebellum) (check the parameters before scanning); (2) T2-FLAIR (brain condition prediction, If any abnormal lesion, The scan should be stopped immediately) (3) T1-weighted 3D-MPRAGE (4) DTI (5) Resting State (BOLD) (positioning line parallel to AC-PC line) (6) MAGiC (7) ASL

  2. Neuropsychological evaluation [patients with moderate brain trauma before or within 48 hours after each scan; For healthy controls matched for sex, age, education, and literacy, Neuropsychological scale assessments were performed at 48 hours after completing the MRI examination.]

    The scale includes pain after TBI, memory, executive function, information processing, TBI recovery, anxiety, and depression.

  3. Hematology and stool data [hematological markers (whole blood samples (0 days), the first MR scan (10~21 days) and 24 hours before (3-6 months after injury), stool samples before the first MR scan and 24 hours before the second MR scan.)]

    collect data of hematological markers (whole blood samples to our hospital (0 days), the first MR scan (10~21 days) and 24 hours before (3-6 months after injury) (3 mL * 2, serum samples 3 mL * 1 / time), collect stool samples (about 1mg) before the first MR scan and 24 hours before the second MR scan.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 60 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • GCS 9-12 points

  • Time for loss of consciousness: 30 minutes-24 hours

  • Forget time after injury: 1-7 days

Exclusion Criteria:
  • Alcohol consumption, substance abuse during or within the previous 24 hours

  • Previous history of traumatic brain injury, MRI contraindication, penetrating brain injury, psychotropic substance use, spinal cord injury, positive neurological examination, multifunctional disorder

  • Neurological and psychiatric history

Contacts and Locations

Locations

Site City State Country Postal Code
1 The First Affiliated Hospital of Xi'an Jiaotong University Xi'an Shaanxi China 710061

Sponsors and Collaborators

  • First Affiliated Hospital Xi'an Jiaotong University
  • Ankang Central Hospital

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
First Affiliated Hospital Xi'an Jiaotong University
ClinicalTrials.gov Identifier:
NCT06099210
Other Study ID Numbers:
  • XJTU1AF2023LSK-194
First Posted:
Oct 25, 2023
Last Update Posted:
Oct 25, 2023
Last Verified:
Oct 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by First Affiliated Hospital Xi'an Jiaotong University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 25, 2023